{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-047342","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.939322+00:00","generated_at":"2026-05-17T01:15:02.797872+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alnylam Q3 net product rev $851M (+103% YoY); raises 2025 guidance 10% to $2.95-3.05B","bullets":["Total net product revenues $851M (+103% YoY); TTR franchise $724M (+135% YoY) led by AMVUTTRA ATTR-CM launch.","GAAP net income $251M ($1.84 diluted EPS) vs loss of $111.6M; non-GAAP net income $396M ($2.90 EPS).","2025 guidance raised: total net product revs $2.95B-$3.05B (10% midpoint increase); TTR rev guidance $2.475B-$2.525B.","Initiated ZENITH Phase 3 for zilebesiran in hypertension and TRITON-PN Phase 3 for nucresiran in hATTR-PN.","Appointed Bryan Supran EVP & Chief Legal Officer; issued $661M convertible notes; received subpoena on government price reporting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-047342","json":"https://secwatch.observer/filing/0001628280-25-047342.json","markdown":"https://secwatch.observer/filing/0001628280-25-047342.md","text":"https://secwatch.observer/filing/0001628280-25-047342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000162828025047342/0001628280-25-047342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000162828025047342/alny-20251030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:15:02.797872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}